Blog
RSS FeedPosted by Michael Wonder on 07 Jun 2023
Bulevirtide acetate for the treatment of adults with chronic hepatitis D (final guidance)
7 June 2023 - NICE has published final evidence based recommendations on the use of bulevirtide (Hepcludex) for the treatment ...
Posted by Michael Wonder on 07 Jun 2023
Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
7 June 2023 - NICE has published final evidence-based recommendations on the use of axicabtagene ciloleucel (Yescarta) for the treatment ...
Posted by Michael Wonder on 07 Jun 2023
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
7 June 2023 - NICE has published final evidence-based recommendations on the use of brexucabtagene autoleucel (Tecartus) for the treatment ...
Posted by Michael Wonder on 06 Jun 2023
Esketamine hydrochloride for the treatment of adults with major depressive disorder at imminent risk of suicide
6 June 2023 - NICE is unable to make a recommendation on the use of esketamine hydrochloride (Spravato) for the treatment ...
Posted by Michael Wonder on 02 Jun 2023
Mosunetuzumab for the treatment of patients with relapsed or refractory follicular lymphoma
31 May 2023 - NICE has published evidence based recommendations on the use of mosunetuzumab (Lunsumio) for the treatment of ...
Posted by Michael Wonder on 31 May 2023
145,000 people in England to have further treatment choice for preventing migraine attacks
31 May 2023 - NICE has for the first time recommended an oral treatment for preventing migraines. ...
Posted by Michael Wonder on 19 May 2023
NICE recommends Rinvoq (upadacitinib) as a treatment option for moderately to severely active Crohn’s disease
18 May 2023 - The NICE recommendation is based on data from three Phase 3 clinical trials demonstrating upadacitinib achieved ...
Posted by Michael Wonder on 18 May 2023
NICE draft guidance recommends new treatment for chronic heart failure
18 May 2023 - Up to 150,000 people in England with a type of chronic heart failure are set to ...
Posted by Michael Wonder on 17 May 2023
Difelikefalin acetate for the treatment of patients with pruritus undergoing haemodialysis
17 May 2023 - NICE has published evidence-based recommendations on the use of difelikefalin acetate (Kapruvia) for the treatment of ...
Posted by Michael Wonder on 17 May 2023
Ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma
17 May 2023 - NICE is unable to make a recommendation on the use of ciltacabtagene autoleucel (Carvykti) for the treatment ...
Posted by Michael Wonder on 17 May 2023
Risankizumab for previously treated moderately to severely active Crohn's disease
17 May 2023 - NICE has published evidence-based recommendations on the use of risankizumab (Skyrizi) for patients 16 years of ...
Posted by Michael Wonder on 10 May 2023
Olaparib for previously treated BRCA mutation positive hormone-relapsed metastatic prostate cancer
10 May 2023 - NICE has published evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate ...
Posted by Michael Wonder on 04 May 2023
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping
3 May 2023 - NICE is unable to make a recommendation on capmatinib (Tabrecta) for treating advanced non-small-cell lung cancer with ...
Posted by Michael Wonder on 03 May 2023
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
3 May 2023 - NICE has issued evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, ...
Posted by Michael Wonder on 03 May 2023
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
3 May 2023 - NICE has issued evidence-based recommendations on tafasitamab (Minjuvi) with lenolidomide for relapsed or refractory diffuse large ...